Mirion Technologies Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Fiscal Year 2023 Financial Guidance

• Revenues for the fourth quarter increased 22.6% to $217.9 million, compared to $177.8 million in the same period in 2021. Adjusted revenues increased 20.5% compared to the fourth quarter of 2021.
• GAAP net loss was $159.7 million in the fourth quarter. Adjusted EBITDA was $56.4 million for the same period.
• GAAP net loss per share for the fourth quarter was $0.85. Adjusted earnings per share for the same period was $0.11.
• The company initiated fiscal year 2023 guidance of 6% to 9% revenue growth, adjusted EBITDA of $172 million to $182 million and adjusted EPS of $0.28 to $0.34.

ATLANTA–(BUSINESS WIRE)–Mirion Technologies, Inc. (“Mirion,” “we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the fourth quarter and fiscal year ended December 31, 2022.

Mirion reported full year order growth for 2022 of approximately 8% compared to 2021. Backlog was $737.4 million as of December 31, 2022, reflecting 10% year-over-year growth, supported by strong engagement with the company’s diverse portfolio of solutions and supportive trends across its end markets. Order growth and backlog exclude the impact of the Hanhikivi project termination in the second quarter of 2022.

“2022 was a dynamic year for Mirion, as we completed our first full year as a public company. Our teams responded well to the myriad of challenges faced throughout the year and we delivered a strong finish to 2022,” stated Thomas Logan, Mirion’s Chief Executive Officer. “Overall, I am very pleased with our fourth quarter results, which were highlighted by substantial revenue growth across both our reporting segments. The Medical business delivered solid top-line growth in all three e and meaningful margin expansion compared to the same period last year. Industrial took a noticeable step forward as well, supported by improved operating conditions and strong execution by our team. We exited 2022 with good momentum and the business is poised to deliver a strong 2023.”

“I am incredibly proud of the growth that Mirion delivered in the fourth quarter. End market demand remains quite healthy and the team has built a strong backlog position to support future growth,” added Larry Kingsley, Chairman of Mirion’s Board of Directors. “I believe that Mirion is well-positioned going into 2023 and beyond, supported by the company’s strategic market position and diverse portfolio of essential products and services.”

The Company recorded goodwill impairment charges of $87.3 million in its Medical segment and $69.3 million in its Industrial segment as a result of its required annual impairment test. The impairment charges represented approximately 10% of the company’s total goodwill balance as of December 31, 2022.

2023 Outlook

“Today, we are providing initial financial guidance for 2023. We are expecting to build off the momentum we established coming out of the fourth quarter,” continued Mr. Logan. “We are anticipating solid top-line growth in 2023, supported by healthy end markets and our robust backlog position. We have taken a thoughtful approach to setting our guidance and believe we have the right strategy in place to execute on our expectations.”

Mirion has issued the following guidance for the fiscal year ending December 31, 2023:

• Reported revenue growth of 6% to 9%, organic growth of 4% to 7%
• Adjusted EBITDA of $172 million – $182 million
• Adjusted EPS of $0.28 – $0.34
• Adjusted free cash flow of $50 million – $70 million

Organic revenue growth is expected at 4% to 7%. Inorganic revenue growth is expected to be approximately 1.5% including benefits from the SIS acquisition, offset by the Biodex physical rehab divestiture, expected to close during the first quarter. Foreign exchange rates are expected to result in a positive 0.5% impact to revenue growth. The guidance for organic revenue growth excludes the impact of foreign exchange rates as well as mergers, acquisitions and divestitures. Other modeling and guidance assumptions include the following:

• Euro to U.S. Dollar foreign exchange conversion rate of 1.07
• Depreciation of approximately $30 million
• Net interest expense of approximately $68 million (approximately $64 million of cash interest)
• Capital expenditures of approximately $40 million
• Effective tax rate of between 25% and 27%
• Approximately 181 million shares of Class A common stock outstanding (excludes 8.0 million shares of Class B common stock, 27.2 million warrants, 18.8 million founder shares, subject to vesting, 1.7 million restricted stock units, 0.4 million performance stock units and a further 23.6 million shares reserved for future equity awards (subject to annual automatic increases)), all as of December 31, 2022

The company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for adjusted revenue, organic adjusted revenue adjusted EBITDA, adjusted EPS and adjusted free cash flow are not available without unreasonable effort.

Conference Call

Mirion will host a conference call today, February 14, 2023 at 10:00 a.m. ET to discuss its financial results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at https://ir.mirion.com/news-events.

A telephonic replay will be available shortly after the conclusion of the call and until February 28, 2023. Participants may access the replay at 1-844-512-2921, international callers may use 1-412-317-6671, and enter access code 13735853. An archived replay of the call and an accompanying presentation will also be available on the Investors section of the Mirion website at https://ir.mirion.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate”, “expect”, “hope”, “intend”, “may”, “might”, “should”, “would”, “will”, “understand” and similar words are intended to identify forward looking statements. These forward-looking statements include but are not limited to, statements regarding our future growth prospects, future financial and operating performance, including our financial guidance and outlook, our order book and backlog, our growth strategy and positioning, market trends, including supply chain hurdles, our competitive positioning, foreign exchange, interest rate and inflation expectations, mergers, acquisitions, divestitures and strategic investments, including completion and integration of previously completed transactions, our future share capitalization and any exercise, exchange or other settlement of our outstanding warrants and other securities. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including changes in domestic and foreign business, market, economic, financial, political and legal conditions, including the Russia-Ukraine conflict and the relationship between the United States and China; risks related to the public’s perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end markets; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology disruption or security; risks related to the implementation and enhancement of information systems; our ability to manage our supply chain or difficulties with third-party manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic transactions, such as acquisitions, divestitures and investments, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt or equity or equity-linked securities in the future; risks related to changes in tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; risks associated with our limited history of operating as an independent company; the impact of the global COVID-19 pandemic, including the availability, acceptance and efficacy of vaccinations, treatments and laws and regulations with respect to vaccinations, on our projected results of operations, financial performance or other financial metrics, or on any of the foregoing risks. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the Securities and Exchange Commission (the “SEC”) from time to time, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other periodic reports filed or to be filed with the SEC.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward- looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Use of Non-GAAP Financial Information

We believe that the presentation of non-GAAP financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition, and results of operations. For further information regarding these non-GAAP measures, including the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please refer to the financial tables below, as well as the “Reconciliation of Non-GAAP Financial Measures” section of this press release.

Basis of Presentation

As a result of the business combination (the “Business Combination”) with GS Acquisition Holdings Corp II (“GSAH”), the company’s financial statement presentation distinguishes Mirion Technologies (TopCo), Ltd (“Mirion TopCo”) as the “Predecessor” until the closing date of the Business Combination, October 20, 2021 (the “Closing Date”). Mirion, which includes the combination of Mirion TopCo and GSAH subsequent to the Business Combination, is the “Successor” for periods starting from the Closing Date. As a result of the application of the acquisition method of accounting in the Successor period, the financial statements for the Successor period are presented on a full step-up basis as a result of the Business Combination, and are therefore not comparable to the financial statements of the Predecessor period that are not presented on the same full step-up basis due to the Business Combination. Mirion adopted a calendar year fiscal year in connection with the closing of the Business Combination.

Channels for Disclosure of Information

Mirion intends to announce material information to the public through the Mirion Investor Relations website ir.mirion.com, SEC filings, press releases, public conference calls and public webcasts. Mirion uses these channels, as well as social media, to communicate with its investors, customers, and the public about the company, its offerings, and other issues. It is possible that the information Mirion posts on social media could be deemed to be material information. As such, Mirion encourages investors, the media, and others to follow the channels listed above, including the social media channels listed on Mirion’s investor relations website, and to review the information disclosed through such channels. Any updates to the list of disclosure channels through which Mirion will announce information will be posted on the investor relations page on Mirion’s website.

About Mirion

Mirion Technologies is a leading provider of detection, measurement, analysis and monitoring solutions to the nuclear, defense, medical and research end markets. The organization aims to harness its unrivaled knowledge of ionizing radiation for the greater good of humanity. Headquartered in Atlanta (GA – USA), Mirion employs around 2,800 people and operates in 13 countries. For more information, and for the latest news and content from Mirion, visit ir.mirion.com.

Mirion Technologies, Inc.
Consolidated Balance Sheets
(Unaudited)
(In millions, except share data)
	Successor									Predecessor
	December 31, 2022				December 31, 2021					June 30, 2021
ASSETS
Current assets:
Cash and cash equivalents	$	73.5			$	84.0				$	101.1
Restricted cash		0.5				0.6					0.8
Accounts receivable, net of allowance for doubtful accounts		171.2				157.4					133.3
Costs in excess of billings on uncompleted contracts		50.0				56.3					57.2
Inventories		143.3				123.6					113.2
Prepaid expenses and other current assets		33.6				31.5					28.3
Assets held for sale		8.5				—					—
Total current assets		480.6				453.4					433.9
Property, plant, and equipment, net		124.3				124.0					88.8
Operating lease right-of-use assets		40.1				45.7					—
Goodwill		1,418.0				1,662.6					681.5
Intangible assets, net		650.4				806.9					326.3
Restricted cash		1.0				0.7					0.5
Other assets		24.3				24.7					16.2
Total assets	$	2,738.7			$	3,118.0				$	1,547.2
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable	$	67.7			$	59.4				$	47.1
Deferred contract revenue		83.0				73.0					50.4
Notes payable to third-parties, current		5.3				3.9					6.4
Operating lease liability, current		8.5				9.3					—
Accrued expenses and other current liabilities		79.8				75.4					84.3
Total current liabilities		244.3				221.0					188.2
Notes payable to related parties, non-current		—				—					1,170.5
Notes payable to third-parties, non-current		801.5				806.8					885.7
Warrant liabilities		30.5				68.1					—
Interest accrued on notes payable to related parties		—				—					64.8
Operating lease liability, non-current		34.3				40.6					—
Deferred income taxes, non-current		116.3				161.0					40.1
Other liabilities		44.6				36.5					37.4
Total liabilities		1,271.5				1,334.0					2,386.7
Commitments and contingencies (Note 11)
Stockholders’ equity (deficit):
Class A common stock; $0.0001 par value, 500,000,000 shares authorized; 200,298,834 shares issued and outstanding at December 31, 2022; 199,523,292 shares issued and outstanding at December 31, 2021		—				—					—
Class B common stock; $0.0001 par value, 100,000,000 shares authorized; 8,040,540 issued and outstanding at December 31, 2022 and 8,560,540 issued and outstanding at December 31, 2021		—				—					—
A Ordinary shares, $0.01 nominal value, 3,000,000 shares authorized, 1,483,795 issued and outstanding at June 30, 2021		—				—					—
B Ordinary shares, $0.01 nominal value, 7,000,000 shares authorized, 5,353,970 issued and outstanding at June 30, 2021		—				—					0.1
Additional paid-in capital		1,882.4				1,845.5					9.5
Receivable from employees for purchase of ordinary shares		—				—					(2.4	)
Accumulated deficit		(408.5	)			(131.6	)				(888.0	)
Accumulated other comprehensive (loss) income		(75.7	)			(20.7	)				39.2
Mirion Technologies, Inc. (Successor) and Mirion Technologies (TopCo), Ltd. (Predecessor) stockholders’ equity (deficit)		1,398.2				1,693.2					(841.6	)
Noncontrolling interests		69.0				90.8					2.1
Total stockholders’ equity		1,467.2				1,784.0					(839.5	)
Total liabilities and stockholders’ equity	$	2,738.7			$	3,118.0				$	1,547.2

Mirion Technologies, Inc.
Consolidated Statements of Operations
(Unaudited)
(In millions, except per share data)
	Successor									Predecessor
	Fiscal Year Ended December 31, 2022				From October 20, 2021 through December 31, 2021					From July 1, 2021 through October 19, 2021				Fiscal Year Ended June 30, 2021				Fiscal Year Ended June 30, 2020
Revenues:
Product	$	533.0			$	120.9				$	123.4			$	459.3			$	353.0
Service		184.8				33.2					44.6				152.3				125.2
Total revenues		717.8				154.1					168.0				611.6				478.2
Cost of revenues:
Product		307.5				83.1					74.0				284.1				216.8
Service		100.2				17.1					23.7				75.7				64.4
Total cost of revenues		407.7				100.2					97.7				359.8				281.2
Gross profit		310.1				53.9					70.3				251.8				197.0
Operating expenses:
Selling, general and administrative		362.3				70.1					101.6				211.2				158.1
Research and development		30.3				6.7					10.3				29.4				15.9
Goodwill impairment		211.8				—					—				—				—
Impairment loss on business held for sale		3.5				—					—				—				—
Total operating expenses		607.9				76.8					111.9				240.6				174.0
(Loss) income from operations		(297.8	)			(22.9	)				(41.6	)			11.2				23.0
Other expense (income):
Third party interest expense		41.9				6.2					12.5				41.0				41.5
Related party interest expense (Note 9)		—				—					40.3				122.2				107.7
Loss on debt extinguishment		—				—					15.9				—				—
Foreign currency loss (gain), net		4.9				1.6					(0.6	)			13.4				(0.6	)
Decrease in fair value of warrant liabilities		(37.6	)			(1.2	)				—				—				—
Other (income) expense, net		(0.4	)			0.3					1.6				(1.1	)			(1.0	)
Loss before income taxes		(306.6	)			(29.8	)				(111.3	)			(164.3	)			(124.6	)
Benefit from income taxes		(18.2	)			(6.8	)				(5.6	)			(5.9	)			(5.5	)
Net loss		(288.4	)			(23.0	)				(105.7	)			(158.4	)			(119.1	)
Loss attributable to noncontrolling interests		(11.5	)			(0.8	)				—				(0.1	)			—
Net loss attributable to Mirion Technologies, Inc. (Successor) / Mirion Technologies (TopCo), Ltd. (Predecessor) stockholders	$	(276.9	)		$	(22.2	)			$	(105.7	)		$	(158.3	)		$	(119.1	)
Net loss per common share attributable to Mirion Technologies, Inc. (Successor) / Mirion Technologies (TopCo), Ltd. (Predecessor) stockholders — basic and diluted	$	(1.53	)		$	(0.12	)			$	(15.81	)		$	(24.18	)		$	(18.45	)
Weighted average common shares outstanding — basic and diluted		181.149				180.773					6.685				6.549				6.453

Mirion Technologies, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
(In millions)
	Successor									Predecessor
	Fiscal Year Ended December 31, 2022				From October 20, 2021 through December 31, 2021					From July 1, 2021 through October 19, 2021				Fiscal Year Ended June 30, 2021				Fiscal Year Ended June 30, 2020
OPERATING ACTIVITIES:
Net loss	$	(288.4	)		$	(23.0	)			$	(105.7	)		$	(158.4	)		$	(119.1	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Accrual of in-kind interest on notes payable to related parties		—				—					40.2				121.2				107.7
Depreciation and amortization expense		174.5				37.3					25.9				83.6				68.4
Stock-based compensation expense		31.8				5.3					9.3				—				0.2
Loss on debt extinguishment		—				—					15.9				—				—
Amortization of debt issuance costs		2.9				0.7					1.1				3.2				2.6
Provision for doubtful accounts		0.3				(0.8	)				0.3				2.1				0.6
Inventory obsolescence write down		0.9				0.3					—				0.7				1.9
Change in deferred income taxes		(37.2	)			(11.2	)				(8.4	)			(16.6	)			(15.5	)
Loss (gain) on disposal of property, plant and equipment		3.4				0.8					1.6				(0.1	)			0.4
Loss (gain) on foreign currency transactions		4.9				1.6					(0.6	)			13.4				(1.7	)
Decrease in fair values of warrant liabilities		(37.6	)			(1.2	)				—				—				—
Amortization of deferred revenue step-down		—				2.3					4.5				8.0				0.2
Amortization of inventory step-up		6.3				15.8					—				5.2				1.6
Goodwill impairment		211.8				—					—				—				—
Other		3.6				(0.1	)				—				1.4				(0.9	)
Changes in operating assets and liabilities:
Accounts receivable		(14.8	)			(42.5	)				18.2				(4.2	)			3.8
Costs in excess of billings on uncompleted contracts		(4.5	)			6.3					(5.7	)			(3.8	)			(2.9	)
Inventories		(34.8	)			5.1					(10.2	)			(4.2	)			2.7
Deferred cost of revenue		(0.8	)			(0.3	)				(0.4	)			6.6				(3.5	)
Prepaid expenses and other current assets		(2.4	)			(2.5	)				2.6				(10.1	)			(1.6	)
Accounts payable		6.3				(8.9	)				19.2				2.6				(2.5	)
Accrued expenses and other current liabilities		5.5				(8.4	)				0.4				(2.2	)			7.3
Deferred contract revenue		6.9				10.6					4.5				(2.8	)			(1.9	)
Other assets		5.7				(6.1	)				(2.2	)			0.5				0.2
Other liabilities		(4.9	)			6.7					2.6				7.5				(8.5	)
Net cash provided by operating activities		39.4				(12.2	)				13.1				53.6				39.5
INVESTING ACTIVITIES:
Acquisition of Mirion, net of cash and cash equivalents acquired		—				(2,124.8	)				—				—				—
Acquisitions of businesses, net of cash and cash equivalents acquired		(6.6	)			(58.6	)				(0.9	)			(290.1	)			(55.7	)
Purchases of property, plant, and equipment and badges		(34.2	)			(6.0	)				(11.6	)			(23.2	)			(19.9	)
Sales of property, plant, and equipment		0.8				—					—				—				—
Proceeds from net investment hedge derivative contracts		0.5				—					—				—				—
Net cash used in investing activities		(39.5	)			(2,189.4	)				(12.5	)			(313.3	)			(75.6	)
FINANCING ACTIVITIES:
Issuances of common stock		—				900.0					—				—				—
Common stock issuance costs		—				(13.3	)				—				—				—
Transaction fees reimbursed by Sellers		—				18.7					—				—				—
Payment of deferred underwriting costs		—				(26.3	)				—				—				—
SPAC share redemption		—				(146.3	)				—				—				—
Borrowings from notes payable to third-parties, net of discount and issuance costs		—				807.3					1.9				218.8				98.8
Principal repayments		(6.6	)			(1.7	)				(2.4	)			(14.8	)			(13.4	)
Deferred financing costs		—				(0.9	)				—				—				—
Borrowings from notes payable – related parties		—				—					—				70.0				—
Borrowing on revolving term loan		—				—					—				—				80.0
Payment on revolving term loan		—				—					—				(35.0	)			(45.0	)
Payment of contingent considerations		—				—					—				—				(2.0	)
Distributions to noncontrolling interests		—				—					—				—				(0.4	)
Other financing		(0.4	)			0.2					1.5				—				0.9
Net cash used in financing activities		(7.0	)			1,537.7					1.0				239.0				118.9
Effect of exchange rate changes on cash, cash equivalents, and restricted cash		(3.2	)			(1.0	)				(0.9	)			3.1				(2.7	)
Net decrease in cash, cash equivalents, and restricted cash		(10.3	)			(664.9	)				0.7				(17.6	)			80.1
Cash, cash equivalents, and restricted cash at beginning of period		85.3				750.2					102.4				120.0				108.7
Cash, cash equivalents, and restricted cash at end of period	$	75.0			$	85.3				$	103.1			$	102.4			$	188.8

Contacts

For investor inquiries:
Jerry Estes

ir@mirion.com

For media inquiries:
Matthew Maddox

mmaddox@mirion.com

Read full story here